US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Eupraxia Pharmaceuticals

8.12

-0.0400-0.49%

Volume:1.48M

Turnover:11.44M

Market Cap:411.26M

PE:-9.23

High:8.21

Open:7.37

Low:7.30

Close:8.16

52wk High:9.32

52wk Low:2.68

Shares:50.65M

Float Shares:39.63M

Volume Ratio:17.52

T/O Rate:3.73%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.8798

EPS(LYR):-0.7642

ROE:-61.02%

ROA:-36.21%

PB:7.05

PE(LYR):-10.63

Loading ...

Overview Company News Filings

Eupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact

Eupraxia Pharmaceuticals Prices $55 Million Public Offering

MT Newswires Live

Eupraxia Pharmaceuticals 6.4M share Spot Secondary priced at $7.00

Eupraxia Pharmaceuticals announces common shares offering, no amount given

Eupraxia Pharmaceuticals Announces Proposed Public Offering

Eupraxia Pharmaceuticals management to meet with Cantor

Eupraxia Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald

Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald

H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus

Benzinga_recent_news

Eupraxia Pharmaceuticals Up Nearly 16%, on Pace for Largest Percent Increase Since November 2024 -- Data Talk

Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results

Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial

Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion

Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/EPRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EPRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPRX\",,,,,undefined,":{"symbol":"EPRX","market":"US","secType":"STK","nameCN":"Eupraxia Pharmaceuticals","latestPrice":8.12,"timestamp":1771534800000,"preClose":8.16,"halted":0,"volume":1479447,"delay":0,"changeRate":-0.004901960784313838,"floatShares":39629000,"shares":50648331,"eps":-0.879812,"marketStatus":"Pre-Mkt","change":-0.04,"latestTime":"02-20 07:52:26 EST","open":7.37,"high":8.21,"low":7.3,"amount":11437045.969868101,"amplitude":0.11152,"askPrice":8.4,"askSize":600,"bidPrice":8.25,"bidSize":546,"shortable":0,"etf":0,"ttmEps":-0.879812,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771597800000},"marketStatusCode":1,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":8.12,"postHourTrading":{"tag":"盘后","latestPrice":8.18,"preClose":8.12,"latestTime":"16:43 EST","volume":203,"amount":1660.67,"timestamp":1771537406797,"change":0.06,"changeRate":0.007389,"amplitude":0.007389},"volumeRatio":17.520855261263453},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPRX\",,,,,undefined,":{"symbol":"EPRX","floatShares":39629000,"roa":"-36.21%","roe":"-61.02%","lyrEps":-0.764151,"volumeRatio":17.520855261263453,"shares":50648331,"dividePrice":0,"high":8.21,"amplitude":0.11152,"preClose":8.16,"low":7.3,"week52Low":2.6801,"pbRate":"7.05","week52High":9.32,"institutionHeld":0,"latestPrice":8.12,"committee":-0.04712,"eps":-0.879812,"divideRate":0,"volume":1479447,"delay":0,"ttmEps":-0.879812,"open":7.37,"prevYearClose":7.55,"prevWeekClose":8.42,"prevMonthClose":8.28,"prevQuarterClose":7.55,"fiveDayClose":8.49,"twentyDayClose":9.03,"sixtyDayClose":6.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EPRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-04","symbol":"EPRX","fiscalQuarterEnding":"2025/09","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":-0.19},{"market":"US","date":"2025-08-12","symbol":"EPRX","fiscalQuarterEnding":"2025/06","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2025-05-06","symbol":"EPRX","fiscalQuarterEnding":"2025/03","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2025-03-20","symbol":"EPRX","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2024-08-07","symbol":"EPRX","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EPRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EPRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":5,"updateTime":1765515600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EPRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EPRX","date":"2026-02-19","current":-9.229244,"percent":0,"low":-16.360804,"twenty":-9.54386,"median":-4.691735,"eighty":-3.394811,"high":-2.890365,"avg":-6.089345,"sd":3.398322,"marketCap":480579770.91},"quantilePoints":[{"date":"2024-04-12","current":-3.449431,"twenty":-3.612259,"median":-3.541416,"eighty":-3.493027,"marketCap":97345692.17},{"date":"2024-04-19","current":-3.387698,"twenty":-3.552309,"median":-3.421661,"eighty":-3.370461,"marketCap":95603540.57},{"date":"2024-04-26","current":-3.593562,"twenty":-3.625516,"median":-3.503926,"eighty":-3.385892,"marketCap":101413189.09},{"date":"2024-05-03","current":-3.426605,"twenty":-3.600947,"median":-3.43788,"eighty":-3.383971,"marketCap":96701521.5},{"date":"2024-05-10","current":-3.385898,"twenty":-3.641329,"median":-3.449431,"eighty":-3.385721,"marketCap":102824445.35},{"date":"2024-05-17","current":-3.411647,"twenty":-3.640071,"median":-3.447632,"eighty":-3.387338,"marketCap":103606411.08},{"date":"2024-05-24","current":-3.304959,"twenty":-3.624933,"median":-3.446108,"eighty":-3.385721,"marketCap":100366460.1},{"date":"2024-05-31","current":-3.138144,"twenty":-3.606012,"median":-3.426605,"eighty":-3.379346,"marketCap":95300524.8},{"date":"2024-06-07","current":-3.18109,"twenty":-3.59449,"median":-3.400672,"eighty":-3.300706,"marketCap":96604762.18},{"date":"2024-06-14","current":-3.114449,"twenty":-3.562274,"median":-3.394505,"eighty":-3.199957,"marketCap":94580945.94},{"date":"2024-06-21","current":-3.113503,"twenty":-3.52642,"median":-3.387698,"eighty":-3.149669,"marketCap":94552230.25},{"date":"2024-06-28","current":-2.999703,"twenty":-3.496261,"median":-3.38264,"eighty":-3.125012,"marketCap":91096288.31},{"date":"2024-07-05","current":-3.012181,"twenty":-3.47937,"median":-3.379233,"eighty":-3.113445,"marketCap":91475249.09},{"date":"2024-07-12","current":-3.187556,"twenty":-3.456124,"median":-3.305072,"eighty":-3.105179,"marketCap":96801126.62},{"date":"2024-07-19","current":-2.929989,"twenty":-3.449376,"median":-3.282654,"eighty":-3.095065,"marketCap":88979206.08},{"date":"2024-07-26","current":-3.134177,"twenty":-3.44886,"median":-3.212535,"eighty":-3.063005,"marketCap":95180061.81},{"date":"2024-08-02","current":-3.030624,"twenty":-3.447364,"median":-3.22865,"eighty":-3.063005,"marketCap":92035318.44},{"date":"2024-08-09","current":-3.555022,"twenty":-3.447364,"median":-3.244765,"eighty":-3.058864,"marketCap":95980604.85},{"date":"2024-08-16","current":-3.425897,"twenty":-3.447364,"median":-3.274173,"eighty":-3.063005,"marketCap":92494393.43},{"date":"2024-08-23","current":-3.341671,"twenty":-3.449376,"median":-3.294326,"eighty":-3.065374,"marketCap":90220410.26},{"date":"2024-08-30","current":-3.353652,"twenty":-3.464811,"median":-3.315197,"eighty":-3.071687,"marketCap":90543888.67},{"date":"2024-09-06","current":-3.290695,"twenty":-3.457797,"median":-3.315197,"eighty":-3.093069,"marketCap":88844129.04},{"date":"2024-09-13","current":-3.351624,"twenty":-3.449431,"median":-3.304959,"eighty":-3.103048,"marketCap":90489126.39},{"date":"2024-09-20","current":-3.738594,"twenty":-3.484763,"median":-3.331473,"eighty":-3.103161,"marketCap":100936771.57},{"date":"2024-09-27","current":-3.383135,"twenty":-3.508398,"median":-3.341671,"eighty":-3.113249,"marketCap":91339879.21},{"date":"2024-10-04","current":-3.46667,"twenty":-3.50577,"median":-3.366161,"eighty":-3.11343,"marketCap":93595226.49},{"date":"2024-10-11","current":-3.161762,"twenty":-3.503926,"median":-3.341671,"eighty":-3.113249,"marketCap":85363132.94},{"date":"2024-10-18","current":-3.344907,"twenty":-3.484763,"median":-3.339004,"eighty":-3.11343,"marketCap":90307790.09},{"date":"2024-10-25","current":-3.261872,"twenty":-3.467153,"median":-3.321915,"eighty":-3.113503,"marketCap":88065960.81},{"date":"2024-11-01","current":-4.073023,"twenty":-3.467153,"median":-3.311841,"eighty":-3.114449,"marketCap":109965883.2},{"date":"2024-11-08","current":-3.993124,"twenty":-3.508398,"median":-3.325322,"eighty":-3.122968,"marketCap":112688263.8},{"date":"2024-11-15","current":-3.927702,"twenty":-3.541416,"median":-3.341027,"eighty":-3.124574,"marketCap":110842028.91},{"date":"2024-11-22","current":-4.430924,"twenty":-3.593562,"median":-3.351624,"eighty":-3.128079,"marketCap":125043241.56},{"date":"2024-11-29","current":-4.297671,"twenty":-3.603509,"median":-3.37867,"eighty":-3.132957,"marketCap":121282763.27},{"date":"2024-12-06","current":-3.937318,"twenty":-3.628014,"median":-3.3817,"eighty":-3.136354,"marketCap":111113399.77},{"date":"2024-12-13","current":-4.300289,"twenty":-3.656263,"median":-3.385015,"eighty":-3.137895,"marketCap":121356641.03},{"date":"2024-12-20","current":-3.802924,"twenty":-3.703016,"median":-3.386798,"eighty":-3.142303,"marketCap":107320735.58},{"date":"2024-12-27","current":-3.93234,"twenty":-3.764328,"median":-3.391081,"eighty":-3.149279,"marketCap":110972914.73},{"date":"2025-01-03","current":-3.832661,"twenty":-3.83089,"median":-3.39476,"eighty":-3.153681,"marketCap":108159910.78},{"date":"2025-01-10","current":-3.777243,"twenty":-3.823171,"median":-3.399132,"eighty":-3.154763,"marketCap":106595986.62},{"date":"2025-01-17","current":-4.056922,"twenty":-3.839064,"median":-3.402373,"eighty":-3.156968,"marketCap":114488699.15},{"date":"2025-01-24","current":-3.831634,"twenty":-3.855819,"median":-3.411647,"eighty":-3.159158,"marketCap":108130926.13},{"date":"2025-01-31","current":-3.881124,"twenty":-3.855819,"median":-3.426251,"eighty":-3.159259,"marketCap":109527578.75},{"date":"2025-02-07","current":-4.05521,"twenty":-3.863924,"median":-3.433627,"eighty":-3.159948,"marketCap":114440377.27},{"date":"2025-02-14","current":-4.035949,"twenty":-3.899488,"median":-3.442651,"eighty":-3.161762,"marketCap":113896828.09},{"date":"2025-02-21","current":-4.691735,"twenty":-3.92863,"median":-3.448417,"eighty":-3.164244,"marketCap":132403473.98},{"date":"2025-02-28","current":-4.985728,"twenty":-3.942572,"median":-3.453351,"eighty":-3.171739,"marketCap":140700111.56},{"date":"2025-03-07","current":-5.272628,"twenty":-3.973604,"median":-3.466617,"eighty":-3.179564,"marketCap":148796613.2},{"date":"2025-03-14","current":-5.235352,"twenty":-4.013632,"median":-3.484763,"eighty":-3.186263,"marketCap":147744675.63},{"date":"2025-03-21","current":-5.143943,"twenty":-4.046869,"median":-3.507084,"eighty":-3.193275,"marketCap":131183594.48},{"date":"2025-03-28","current":-4.683166,"twenty":-4.084769,"median":-3.523754,"eighty":-3.206159,"marketCap":119432606.84},{"date":"2025-04-04","current":-4.101903,"twenty":-4.144484,"median":-3.54588,"eighty":-3.211833,"marketCap":104608925.61},{"date":"2025-04-11","current":-4.181878,"twenty":-4.156687,"median":-3.555418,"eighty":-3.233723,"marketCap":106648501.77},{"date":"2025-04-17","current":-4.623736,"twenty":-4.175739,"median":-3.595883,"eighty":-3.239438,"marketCap":117916996.55},{"date":"2025-04-25","current":-5.41667,"twenty":-4.199429,"median":-3.609908,"eighty":-3.239815,"marketCap":138138823.95},{"date":"2025-05-02","current":-5.613333,"twenty":-4.264738,"median":-3.621205,"eighty":-3.242792,"marketCap":143154231.65},{"date":"2025-05-09","current":-5.295999,"twenty":-4.315353,"median":-3.640408,"eighty":-3.244752,"marketCap":138872234.38},{"date":"2025-05-16","current":-5.22877,"twenty":-4.436885,"median":-3.652794,"eighty":-3.248222,"marketCap":137109346.32},{"date":"2025-05-23","current":-5.086528,"twenty":-4.497055,"median":-3.683127,"eighty":-3.254144,"marketCap":133379475.66},{"date":"2025-05-30","current":-5.353206,"twenty":-4.57142,"median":-3.705394,"eighty":-3.256702,"marketCap":140372329.16},{"date":"2025-06-06","current":-5.498899,"twenty":-4.688307,"median":-3.727372,"eighty":-3.257371,"marketCap":144192703.66},{"date":"2025-06-13","current":-5.361342,"twenty":-4.755446,"median":-3.735365,"eighty":-3.25942,"marketCap":140585698.02},{"date":"2025-06-20","current":-6.021317,"twenty":-4.844055,"median":-3.755654,"eighty":-3.26156,"marketCap":157891599.42},{"date":"2025-06-27","current":-6.394464,"twenty":-4.984149,"median":-3.780835,"eighty":-3.263694,"marketCap":167676310.99},{"date":"2025-07-03","current":-7.487464,"twenty":-5.086528,"median":-3.792925,"eighty":-3.270982,"marketCap":196337074.41},{"date":"2025-07-11","current":-7.62232,"twenty":-5.143943,"median":-3.801523,"eighty":-3.275156,"marketCap":199873266.74},{"date":"2025-07-18","current":-7.38883,"twenty":-5.177531,"median":-3.819467,"eighty":-3.277364,"marketCap":193750685.21},{"date":"2025-07-25","current":-7.574057,"twenty":-5.210176,"median":-3.832148,"eighty":-3.277562,"marketCap":198607730.41},{"date":"2025-08-01","current":-7.369401,"twenty":-5.244258,"median":-3.855819,"eighty":-3.290209,"marketCap":193241210.3},{"date":"2025-08-08","current":-7.353701,"twenty":-5.256616,"median":-3.862136,"eighty":-3.290695,"marketCap":192829519.9},{"date":"2025-08-15","current":-6.515547,"twenty":-5.287548,"median":-3.881124,"eighty":-3.293384,"marketCap":188662911.97},{"date":"2025-08-22","current":-6.435294,"twenty":-5.330379,"median":-3.902951,"eighty":-3.294326,"marketCap":186339119.08},{"date":"2025-08-29","current":-6.443249,"twenty":-5.361342,"median":-3.927702,"eighty":-3.29841,"marketCap":186569475.43},{"date":"2025-09-05","current":-6.594946,"twenty":-5.398376,"median":-3.933623,"eighty":-3.303649,"marketCap":190961969.86},{"date":"2025-09-12","current":-6.795439,"twenty":-5.448392,"median":-3.947836,"eighty":-3.305049,"marketCap":196767403.48},{"date":"2025-09-19","current":-7.504554,"twenty":-5.562315,"median":-3.961669,"eighty":-3.315902,"marketCap":217300397.06},{"date":"2025-09-26","current":-7.177732,"twenty":-5.598125,"median":-3.989698,"eighty":-3.321254,"marketCap":207837019.06},{"date":"2025-10-03","current":-10.41009,"twenty":-5.766572,"median":-4.012411,"eighty":-3.324641,"marketCap":301432553.8},{"date":"2025-10-10","current":-10.720754,"twenty":-6.007438,"median":-4.037645,"eighty":-3.335164,"marketCap":310428066.15},{"date":"2025-10-17","current":-10.15161,"twenty":-6.40263,"median":-4.05521,"eighty":-3.339831,"marketCap":293948056.76},{"date":"2025-10-24","current":-9.839558,"twenty":-6.476402,"median":-4.069956,"eighty":-3.341413,"marketCap":284912320.02},{"date":"2025-10-31","current":-9.373299,"twenty":-6.573065,"median":-4.13169,"eighty":-3.34426,"marketCap":271411444.71},{"date":"2025-11-07","current":-9.699849,"twenty":-6.613334,"median":-4.138877,"eighty":-3.350281,"marketCap":284921875.51},{"date":"2025-11-14","current":-10.803812,"twenty":-6.67166,"median":-4.151036,"eighty":-3.353246,"marketCap":317349508.66},{"date":"2025-11-21","current":-10.8778,"twenty":-6.689916,"median":-4.163525,"eighty":-3.373666,"marketCap":319522857.51},{"date":"2025-11-28","current":-10.814452,"twenty":-6.746599,"median":-4.176559,"eighty":-3.379346,"marketCap":317662080.57},{"date":"2025-12-05","current":-9.965856,"twenty":-6.97961,"median":-4.181878,"eighty":-3.380077,"marketCap":292735526.92},{"date":"2025-12-12","current":-11.086677,"twenty":-7.160673,"median":-4.205443,"eighty":-3.381987,"marketCap":325658373.25},{"date":"2025-12-19","current":-10.90031,"twenty":-7.261302,"median":-4.255979,"eighty":-3.383716,"marketCap":320184040.95},{"date":"2025-12-26","current":-12.631802,"twenty":-7.339109,"median":-4.297671,"eighty":-3.384468,"marketCap":371044617.8},{"date":"2026-01-02","current":-12.965446,"twenty":-7.369059,"median":-4.309912,"eighty":-3.385184,"marketCap":380845039.89},{"date":"2026-01-09","current":-14.785144,"twenty":-7.418048,"median":-4.386192,"eighty":-3.385869,"marketCap":434296571.54},{"date":"2026-01-16","current":-15.389028,"twenty":-7.520623,"median":-4.445826,"eighty":-3.386258,"marketCap":452034968.62},{"date":"2026-01-23","current":-15.580982,"twenty":-7.574388,"median":-4.464922,"eighty":-3.387698,"marketCap":457673379.52},{"date":"2026-01-30","current":-14.457625,"twenty":-7.65829,"median":-4.510416,"eighty":-3.38827,"marketCap":424676100},{"date":"2026-02-06","current":-14.5446,"twenty":-7.863135,"median":-4.596564,"eighty":-3.393892,"marketCap":427230871.96},{"date":"2026-02-13","current":-13.989424,"twenty":-9.489561,"median":-4.653451,"eighty":-3.394505,"marketCap":410923224.77},{"date":"2026-02-19","current":-16.360804,"twenty":-9.54386,"median":-4.691735,"eighty":-3.394811,"marketCap":480579770.91}],"updateTime":1771591946208},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EPRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612269455","title":"Eupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact","url":"https://stock-news.laohu8.com/highlight/detail?id=2612269455","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612269455?lang=en_us&edition=fundamental","pubTime":"2026-02-20 19:32","pubTimestamp":1771587170,"startTime":"0","endTime":"0","summary":"An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On February 18, 2026, Eupraxia Pharmaceuticals entered into an underwriti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-launches-cross-border-equity-and-warrant-offering-under-new-underwriting-pact?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-launches-cross-border-equity-and-warrant-offering-under-new-underwriting-pact?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","BK4585","EQR","BK4139","EPRX","BK4588"],"gpt_icon":0},{"id":"2612628082","title":"Eupraxia Pharmaceuticals Prices $55 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2612628082","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612628082?lang=en_us&edition=fundamental","pubTime":"2026-02-20 04:06","pubTimestamp":1771531566,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals  said Thursday it priced a public offering of about 6.4 million shares at $7 per share and pre-funded warrants to purchase roughly 1.4 million shares at $6.99999 per warrant, for gross proceeds of approximately $55 million.Each pre-funded warrant entitles the holder to purchase one common share at an exercise price of CA$0.00001  per share and will not expire until exercised in full. The company granted underwriters a 30-day option to purchase up to 1,178,571 additional common shares on the same terms.The offering is expected to close on Feb. 20.Eupraxia said it plans to use the net proceeds primarily to advance EP-104GI for Eosinophilic Esophagitis. A portion will also support additional gastrointestinal indications, research and development, business development and general corporate purposes.Shares of the company were down more than 4% in recent trading.Price: 7.81, Change: -0.35, Percent Change: -4.29","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2612401522","title":"Eupraxia Pharmaceuticals 6.4M share Spot Secondary priced at $7.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2612401522","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612401522?lang=en_us&edition=fundamental","pubTime":"2026-02-19 19:10","pubTimestamp":1771499434,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald and LifeSci Capital acted as joint book running managers for the offering. Published first on TheFly – the ultimate source for re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-6-4m-share-spot-secondary-priced-at-7-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-6-4m-share-spot-secondary-priced-at-7-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2612005429","title":"Eupraxia Pharmaceuticals announces common shares offering, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2612005429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612005429?lang=en_us&edition=fundamental","pubTime":"2026-02-19 05:11","pubTimestamp":1771449115,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (EPRX) announced the company has filed a preliminary prospectus supplement to its short form base shelf prospectus dated F...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-announces-common-shares-offering-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-announces-common-shares-offering-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2612041429","title":"Eupraxia Pharmaceuticals Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2612041429","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612041429?lang=en_us&edition=fundamental","pubTime":"2026-02-19 05:01","pubTimestamp":1771448460,"startTime":"0","endTime":"0","summary":"VICTORIA, British Columbia, Feb.  18, 2026  (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240603/0/en/Eupraxia-Pharmaceuticals-Announces-Proposed-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2608258894","title":"Eupraxia Pharmaceuticals management to meet with Cantor","url":"https://stock-news.laohu8.com/highlight/detail?id=2608258894","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608258894?lang=en_us&edition=fundamental","pubTime":"2026-02-03 02:55","pubTimestamp":1770058509,"startTime":"0","endTime":"0","summary":"Meeting to be held in New York on February 2-6 hosted by Cantor. Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-management-to-meet-with-cantor-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-management-to-meet-with-cantor-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2603607498","title":"Eupraxia Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2603607498","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603607498?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:49","pubTimestamp":1768481340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 15, 2026 07:49 ET (12:49 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"gpt_icon":0},{"id":"2603349607","title":"Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2603349607","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603349607?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:35","pubTimestamp":1768480551,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald raised the firm’s price target on Eupraxia Pharmaceuticals (EPRX) to $19 from $11 and keeps an Overweight rating on the shares. E...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-price-target-raised-to-19-from-11-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-price-target-raised-to-19-from-11-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX"],"gpt_icon":0},{"id":"2602032048","title":"H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602032048","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602032048?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:36","pubTimestamp":1767958597,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Eupraxia Pharmaceuticals today and set a price target of $12.00. According to Tip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-eupraxia-pharmaceuticals-eprx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-eupraxia-pharmaceuticals-eprx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX"],"gpt_icon":0},{"id":"2602832035","title":"Eupraxia Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2602832035","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602832035?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:24","pubTimestamp":1767957840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 06:24 ET (11:24 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"gpt_icon":0},{"id":"2602947033","title":"Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus","url":"https://stock-news.laohu8.com/highlight/detail?id=2602947033","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602947033?lang=en_us&edition=fundamental","pubTime":"2026-01-09 02:10","pubTimestamp":1767895800,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission in EoE patients, with no serious safety issues reported.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/08/X-ray-Anterior-Or-Front-View-Of-The-Esop.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/08/X-ray-Anterior-Or-Front-View-Of-The-Esop.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49794109/eupraxia-trial-data-shows-lasting-tissue-healing-in-patients-with-inflamed-esophagus","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/01/49794109/eupraxia-trial-data-shows-lasting-tissue-healing-in-patients-with-inflamed-esophagus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2582804472","title":"Eupraxia Pharmaceuticals Up Nearly 16%, on Pace for Largest Percent Increase Since November 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2582804472","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582804472?lang=en_us&edition=fundamental","pubTime":"2025-11-11 03:30","pubTimestamp":1762803000,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, Inc.  is currently at $6.31, up $0.86 or 15.78%. --Would be highest close since Sept. 22, 2025, when it closed at $6.65. --On pace for largest percent increase since Nov. 1, 2024, when it rose 28.36%. --Up 99.05% year-to-date; on pace for best year on record . --Down 6.88% from its all-time closing high of $6.78 on July 6, 2023. --Up 109.63% from 52 weeks ago , when it closed at $3.01. --Traded as high as $6.32; highest intraday level since Sept. 23, 2025, when it hit $6.41","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2581675747","title":"Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581675747","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581675747?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:43","pubTimestamp":1762292613,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48639239/eupraxia-pharmaceuticals-q3-eps-0-19-beats-0-21-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"gpt_icon":0},{"id":"2581767111","title":"Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581767111","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581767111?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:39","pubTimestamp":1762292340,"startTime":"0","endTime":"0","summary":"Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180937/0/en/Eupraxia-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2581762090","title":"Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581762090","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581762090?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:33","pubTimestamp":1762292015,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an update. Eupraxia Pharmaceuticals Inc. released its consolidated financial statements and man...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-releases-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-releases-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2578620112","title":"Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2578620112","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578620112?lang=en_us&edition=fundamental","pubTime":"2025-10-28 03:38","pubTimestamp":1761593885,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, Inc. (($TSE:EPRX)) announced an update on their ongoing clinical study. Study Overview: Eupraxia Pharmaceuticals, Inc. is...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-advances-eoe-treatment-with-ep-104gi-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-advances-eoe-treatment-with-ep-104gi-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","EP","BK4139","BK4213"],"gpt_icon":0},{"id":"2572558958","title":"Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2572558958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572558958?lang=en_us&edition=fundamental","pubTime":"2025-10-01 23:18","pubTimestamp":1759331901,"startTime":"0","endTime":"0","summary":"An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On September 29, 2025, Eupraxia Pharmaceuticals announced positive data f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-positive-results-in-eoe-trial-and-plans-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-positive-results-in-eoe-trial-and-plans-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2571032258","title":"Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571032258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571032258?lang=en_us&edition=fundamental","pubTime":"2025-09-30 23:35","pubTimestamp":1759246535,"startTime":"0","endTime":"0","summary":"In a report released today, from Raymond James reiterated a Buy rating on Eupraxia Pharmaceuticals, with a price target of $12.00. The company’s sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","RJF"],"gpt_icon":0},{"id":"2571936370","title":"Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2571936370","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571936370?lang=en_us&edition=fundamental","pubTime":"2025-09-30 05:06","pubTimestamp":1759179964,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an update. On September 24, 2025, Eupraxia Pharmaceuticals Inc. announced the successful clos...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-closes-80-5-million-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-closes-80-5-million-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2571363471","title":"Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2571363471","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571363471?lang=en_us&edition=fundamental","pubTime":"2025-09-30 05:00","pubTimestamp":1759179600,"startTime":"0","endTime":"0","summary":"Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3158170/0/en/Eupraxia-Pharmaceuticals-Announces-Positive-Data-from-Highest-Dose-Cohort-in-the-Ongoing-RESOLVE-Trial-in-Eosinophilic-Esophagitis-and-Plans-for-Expansion-of-EP-104GI-Development-P.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EP","BK4139","BK4213","EPRX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}